Please login to the form below

Bluebird Bio

This page shows the latest Bluebird Bio news and features for those working in and with pharma, biotech and healthcare.

Regeneron and Bluebird sign $100m cell therapies deal

Big biotech’Regeneron and cell and gene therapy specialists Bluebird Bio have unveiled a new collaboration which gives both greater presence in next-generation cell therapies. ... The collaboration with Regeneron complements Bluebird Bio’s growing

Latest news

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

Other companies which have PRIME status include gene therapy specialists Bluebird Bio, who are expected to file their LentiGlobin therapy for beta thalassemia later this year.
Bluebird’s first gene therapy gets European fast track

Gene therapy company Bluebird Bio is on course to file its first product later this year, and has just been granted an accelerated review by the European Medicines Agency. ... Bluebird Bio: on the cusp of a gene therapy revolution (PME July/August
Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more

While Bluebird Bio impressed with further strong data on beta thalassemia and sickle cell disease on Friday, the following data saw Novartis and Celgene both unveil longer-term data in DLBCL –
More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease

One of the standouts amid all the other blood cancer therapy data released this morning were two updates from Cambridge, Mass-based biotech Bluebird Bio. ... M.D., chief medical officer, Bluebird Bio. Europe’s regulatory the EMA has granted the therapy
J&J moves quickly ahead with trials of myeloma CAR-T

J&J is going up against some well-positioned competitors in the anti-BCMA CAR-T category, notably Celgene and Bluebird Bio with bb2121, Celgene and Juno with and Kite

More from news
Approximately 6 fully matching, plus 17 partially matching documents found.

Latest Intelligence

Bluebird Bio: on the cusp of a gene therapy revolution

Bluebird Bio: on the cusp of a gene therapy revolution. Nick Leschly talks to PME about Bluebird's remarkable gene therapy pipeline and why it’s filing first in Europe. ... The next company to play its hand in this biotech-led transformation of
Deal Watch September 2016

The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 1, 695. Medigene /Bluebird bio. Licence. Development and
Pharma deals in May 2015

Interestingly though, it is not always the major players as evidenced by the deals between bluebird bio with Five Prime Therapeutics and Editas with Juno Therapeutics. ... Five Prime/ bluebird bio. Licence agreement. For development of CAR-T cell
Deal Watch table for June 2014

208. Pregenen/ bluebird bio. Company acquisition. Gene editing technology platform. 156.
Pharma deals during March 2013

344. Bluebird bio/ Celgene Corporation. Option &licence. CAR T-cell therapy for oncology (platform).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal. The US biotech could receive $70m in development milestones for the candidate. ... Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy
Proteostasis Therapeutics strengthens leadership team

James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia.

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Associate Scientific Director: Salary TBC

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Healthcare PR Senior Account Manager: Salary TBC

Medical Writer - Creative and Scientific Projects: DOE

Account Manager- 4 days per week or full-time: Salary TBC

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Writer, Healthcare Advertising, London: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Manager: Negotiable

Senior Medical Writer: Salary is DOE

Account Director - Digital: Great salary and benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Subscribe to our email news alerts

PMHub

Add my company

M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Solaris Health looks at the gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...